Arcturus Therapeutics Holdings (ARCT) Revenue (2018 - 2026)

Arcturus Therapeutics Holdings (ARCT) has 9 years of Revenue data on file, last reported at $2.1 million in Q1 2026.

• Quarterly Revenue fell 92.99% year-over-year to $2.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $54.7 million (down 61.92% YoY) and the FY2025 annual result came in at $82.0 million, down 46.14% from the prior year.
• Revenue retreated to $2.1 million in Q1 2026, from $7.2 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $160.3 million in Q4 2022 to a low of $2.1 million in Q1 2026.
• A 5-year average of $35.8 million and a median of $28.3 million in 2025 frame the typical range for Revenue.
• Annual changes were most pronounced in 2022 — Revenue soared 2666.53% — and 2026, when it sank 92.99%.
• Tracing ARCT's Revenue over 5 years: stood at $160.3 million in 2022, then plunged by 80.75% to $30.9 million in 2023, then dropped by 26.22% to $22.8 million in 2024, then sank by 68.39% to $7.2 million in 2025, then sank by 71.36% to $2.1 million in 2026.
• The last three Revenue figures came in at $2.1 million (Q1 2026), $7.2 million (Q4 2025), and $17.2 million (Q3 2025), per Business Quant data.